Targeted therapy prolongs life in patients with HER2-positive breast cancer

SAN ANTONIO -- Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium. Link:  http://www.dukemednews.org

Read the whole article on Science Blog

More from Science Blog